These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 15058159

  • 1. [Soluble receptors of cytokines in sera of patients with systemic sclerosis--clinical correlation].
    Lis AD, Brzezińska-Wcisło LA.
    Wiad Lek; 2003; 56(11-12):532-6. PubMed ID: 15058159
    [Abstract] [Full Text] [Related]

  • 2. Soluble cytokine receptors in renal vasculitis and lupus nephritis.
    Tesar V, Jirsa M, Zima T, Kalousová M, Bartunková J, Stejskalová A, Dostál C, Zabka J.
    Med Sci Monit; 2002 Jan; 8(1):BR24-9. PubMed ID: 11782670
    [Abstract] [Full Text] [Related]

  • 3. [Soluble cytokinin receptors in renal vasculitis and lupus nephritis].
    Tesar V, Jirsa M, Masek Z, Bartůnková J, Stejskalová A, Dostál C, Zabka J, Chábová V, Rysavá R.
    Cas Lek Cesk; 1998 May 04; 137(9):271-5. PubMed ID: 9650355
    [Abstract] [Full Text] [Related]

  • 4. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma.
    Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K.
    Br J Dermatol; 1996 May 04; 134(5):843-7. PubMed ID: 8736323
    [Abstract] [Full Text] [Related]

  • 5. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels.
    Polisson RP, Gilkeson GS, Pyun EH, Pisetsky DS, Smith EA, Simon LS.
    J Rheumatol; 1996 Apr 04; 23(4):654-8. PubMed ID: 8730122
    [Abstract] [Full Text] [Related]

  • 6. Soluble serum interleukin 2 receptors in patients with systemic sclerosis.
    Steen VD, Engel EE, Charley MR, Medsger TA.
    J Rheumatol; 1996 Apr 04; 23(4):646-9. PubMed ID: 8730120
    [Abstract] [Full Text] [Related]

  • 7. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis.
    Majewski S, Wojas-Pelc A, Malejczyk M, Szymanska E, Jablonska S.
    Acta Derm Venereol; 1999 May 04; 79(3):207-10. PubMed ID: 10384918
    [Abstract] [Full Text] [Related]

  • 8. [Interleukin-2 and interleukin-6 in serum as markers of disease progression in systemic sclerosis].
    Lis A, Brzezińska-Wcisło L.
    Pol Merkur Lekarski; 2001 Sep 04; 11(63):206-9. PubMed ID: 11761811
    [Abstract] [Full Text] [Related]

  • 9. Soluble TNF and IL-2 receptors in patients with breast cancer.
    Tesarová P, Kvasnicka J, Umlaufová A, Homolková H, Jirsa M, Tesar V.
    Med Sci Monit; 2000 Sep 04; 6(4):661-7. PubMed ID: 11208388
    [Abstract] [Full Text] [Related]

  • 10. Changes in sIL-6R and sTNF-Rs release by PMNs and the serum levels in breast cancer patients at different stages of treatment.
    Jablonska E.
    Cytokine; 1998 Jul 04; 10(7):540-3. PubMed ID: 9702418
    [Abstract] [Full Text] [Related]

  • 11. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
    Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K.
    J Rheumatol; 1998 Feb 04; 25(2):308-13. PubMed ID: 9489824
    [Abstract] [Full Text] [Related]

  • 12. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma.
    Nagaoka T, Sato S, Hasegawa M, Ihn H, Takehara K.
    J Rheumatol; 2000 Aug 04; 27(8):1917-21. PubMed ID: 10955333
    [Abstract] [Full Text] [Related]

  • 13. [Level of soluble tumor necrosis factor receptor type I in patients with systemic scleroderma].
    Alekperov RT, Timchenko AV, Samsonov MIu, Guseva NG, Nasonov EL.
    Ter Arkh; 2004 Aug 04; 76(5):11-5. PubMed ID: 15230124
    [Abstract] [Full Text] [Related]

  • 14. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk.
    Pulsatelli L, Boiardi L, Pignotti E, Dolzani P, Silvestri T, Macchioni P, Cantini F, Salvarani C, Facchini A, Meliconi R.
    Arthritis Rheum; 2008 Aug 15; 59(8):1147-54. PubMed ID: 18668607
    [Abstract] [Full Text] [Related]

  • 15. Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis.
    Nassonov EL, Samsonov MY, Tilz GP, Beketova TV, Semenkova EN, Baranov A, Wachter H, Fuchs D.
    J Rheumatol; 1997 Apr 15; 24(4):666-70. PubMed ID: 9101499
    [Abstract] [Full Text] [Related]

  • 16. In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis.
    Gruschwitz MS, Albrecht M, Vieth G, Haustein UF.
    J Rheumatol; 1997 Oct 15; 24(10):1936-43. PubMed ID: 9330935
    [Abstract] [Full Text] [Related]

  • 17. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.
    Lee YJ, Shin KC, Kang SW, Lee EB, Kim HA, Song YW.
    Clin Exp Rheumatol; 2001 Oct 15; 19(1):69-74. PubMed ID: 11247328
    [Abstract] [Full Text] [Related]

  • 18. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet's disease: correlations with disease activity and severity.
    Yosipovitch G, Shohat B, Bshara J, Wysenbeek A, Weinberger A.
    Isr J Med Sci; 1995 Jun 15; 31(6):345-8. PubMed ID: 7607852
    [Abstract] [Full Text] [Related]

  • 19. [Soluble TNF and IL-2 receptors in patients with breast carcinoma].
    Tesarová P, Kvasnicka J, Umlaufová A, Homolková J, Jirsa M, Tesar V.
    Cas Lek Cesk; 1998 May 25; 137(11):341-5. PubMed ID: 9727208
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-6, soluble interleukin-2-receptor and soluble interleukin-6-receptor in sera of patients with rheumatoid arthritis: influences of disease activity and drug therapy.
    Franke S, Herrmann D, Hein G, Müller A, Stein G.
    Eur J Med Res; 1997 Sep 29; 2(9):401-6. PubMed ID: 9300938
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.